Navigation Links
Bioequivalence and Bioavailability Survey Report

LONDON, June 23, 2011 /PRNewswire/ --


Pharma IQ has just published the results of an Industry-wide Bioequivalence and Bioavailability Survey, conducted recently among 2,000 bioequivalence and bioavailability experts.

The results showed that 33.3% of respondents found the ability to secure biowaivers as their main concern; another third said it was validating IVIVC. Two-thirds of the respondents said that the most important factor when choosing a service provider was a strong working relationship. Only a third of companies were more concerned by the upfront cost, while a CRO's reputation alone would not be enough to sway any of the participants.

With regard to the satisfaction with their current service providers, 66.7% of companies would not rush to change service provider while the remaining third claimed to be not entirely pleased with their partner's offering.

The survey was created as a part of the pre-conference research for 2nd Annual Bioequivalence and Bioavailability Studies, taking place 19-20 September, 2011 in Brussels. The results helped to shape the agenda and the final speaker line-up which features AGES providing the delegates with an overview of current guidelines and National Institute for Pharmacy Directorate from Hungary sharing a regulatory perspective on the EMA bioequivalence guideline one year on. BfArM will outline the EU guideline on the validation of bioanalytical methods.

Other important topics expressed by survey respondents and will be discussed at the event include:

  • Translating (non-) bioequivalence results to clinical (IR) relevance through integrated modelling and simulation of PK/PD- efficacy/safety - Case Study from Merck
  • Challenges in the design of comparative bioavailability studies: experiences from industry - Case Study from Synthon BV
  • Industry experience with the EMA bioequivalence guideline - Case Study from EGA Bioequivalence Working Group

  • Tips from the regulators for successfully securing a biowaiver (State Institute for Drug Control, Czech Republic)

To access the full survey report or to find out more about Bioequivalence and Bioavailability Studies 2011 please visit Bioequivalence and Bioavailability page, email or call +44(0)2073689421

Media contact: Joanna Checinska, +44(0)20-7368-9421,  - Please contact for more information or images.

Press are invited to attend this important industry forum, if you would like to a complimentary press pass please email Joanna Checinska (

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
2. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
3. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
4. MannKind Reports Successful Completion of Device Bioequivalence Trial
5. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
6. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
7. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
8. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
9. NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
10. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
11. Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... transport experience for the millions of people who require these medical transport services ... industry through the use of technology. Now, SmartEMS has put forth an industry-changing ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):